C3N-01823
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 63.85215606
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1408113 | GTEX | — | 0.749 |
| 2 | MNG90 | — | — | 0.729 |
| 3 | MNG598 | — | — | 0.727 |
| 4 | SRR1452056 | GTEX | — | 0.724 |
| 5 | SRR12696806 | — | — | 0.720 |
| 6 | SRR1430817 | GTEX | — | 0.713 |
| 7 | MNG1131 | — | — | 0.713 |
| 8 | MNG1185 | — | — | 0.710 |
| 9 | SRR1439674 | GTEX | — | 0.710 |
| 10 | SRR1341008 | GTEX | — | 0.709 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.050 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.040 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.020 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.010 | Idelalisib | — uncovered |